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Abstract 
Variceal bleeding is one of the dreaded complications of portal hypertension. Although its prognosis has improved over 
the last several decades, it still carries substantial mortality. Although most portal hypertensive bleeds result from the 
ruptured distal esophageal varices, bleeding from other sources such gastric varices, portal hypertensive gastropathy, 
and ectopic varices can lead to clinically significant bleeding. 
Variceal bleeding typically presents as massive gastrointestinal (GI) bleeding with hematemesis, melena or 
hematochezia. In general, the terapeutic aims of management are to initially correct hypovolemia, to control bleeding, to 
prevent complications of bleeding, such as infection and renal failure and to prevent early rebleeding. 
The treatment of bleeding esophageal varices differs substantially foom the treatment of other lesions of the upper 
gastrointestinal tract. Moreover, patients with esophageal varices typically have severe liver disease and thus are likely 
from poor nutrition, blood clotting disorders, and encephalopathy, all of which can adversaly affect morbidity and 
mortality.  
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Introduction 
When patients who have cirrhosis present with 
GI bleeding, they should be resuscitated and receive 
vasoactive agents such as: octreotide or vasopressin. All 
patients with variceal upper gastrointestinal bleeding 
should undergo upper endoscopy, performed after the 
patient is hemodynamically stable. Endoscopy should be 
performed promptly to diagnose the source of bleeding 
and to provide endoscopic therapy (preferably banding). 
The currently available treatment for acute variceal 
bleeding provides hemostasis in most patients. 
 
Stabilization 
The hemodynamic instability related to 
hypovolemia is a common presentation of acute variceal 
bleeding. Therefore, patients require prompt resuscitation, 
hemodynamic support, and correction of hemodynamic 
dysfunction, which usually requires intensive care unit 
monitoring [1]. Judicios transfusion of blood products is 
necessary. Hemoglobin between 9 and 12g/dl is the 
target when transfusing cirrhotic patients who have 
variceal bleeding. In actively bleeding patients, platelets 
are transfuzed if the platelet count is under 50.000/ul. 
Fresh frozen plasma is administered for actively bleeding 
patients with a coagulopathy and an INR>1,5. 
Endotracheal intubation for airway protection 
should be considered in anyone who is at risk for 
aspiration or is uncooperative.  
Renal failure is a common complication of 
cirrhotic patients hospitalized for variceal bleeding [2]. The 
cause is typically multifactorial, including prolonged 
hypovolemia, overuse of diuretics, infection and 
hepatorenal syndrome. Renal failure is an independent 
risk factor for in-hospital mortality. Therefore, every effort 
should be made to avoid the development of renal failure 
by early aggresive resuscitation of patients and by 
avoiding nephrotoxic agents such as aminoglycosides 
and nonsteroidal drugs.  
Recent studies have shown the importance of 
using prophylactic antibiotics in cirrhotic patients with 
bleeding. Bacterial infections are more common in 
cirrhotic patients with variceal bleeding (35% to 66%) then 
in noncirrhotic hospitalized patients (5% to 7%) [3]. Two 
factors have been identified to increase the risk of 
bacterial infections: severity of the liver disease and GI Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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hemorrhage. In patients who have cirrhosis with variceal 
hemorrhage, prophylaxis against a bacterial infection 
reduces variceal rebleeding and improves survival [4]. 
The most common causes of bacterial infections in 
patients who had cirrhosis, with variceal bleeding, 
included spontaneous bacterial peritonitis, urinary tract 
infection and pneumonia. Typically gram-negative 
organisms are isolated.  Therefore, antibiotics (oral 
quinolones or intravenous cephalosporins) should be 
given for 7 days in patients who have cirrhosis with 
bleeding [5]. 
As a part of the initial stabilization, balloon 
tamponade with a Sengtaken-Blakemore tube may be 
necessary to control brisk bleeding. Ballon tamponade 
succesfully achieves hemostasis in 90% of the cases of 
bleeding varices, but it has a high recurrence rate for 
rebleeding once the balloon is deflated. 
 
Vasoactive agents  
Vasoactive agents for treating bleeding 
esophageal varices first were described in 1962. 
Vasopressin was the first agent studied because of its 
ability to induce splanchnic vasoconstriction, which leads 
to a decrease in portal inflow and portal pressure. 
Vasopresin’s cardiovascular adverse effects, such as 
myocardial ischemia and infarction, were limited in use.  
Somatostatin is a natural peptide that induces 
splanchnic vasoconstristion which leads to a decreae in 
portal pressure. In four unblinded randomized studies, 
compared with placebo, somatostatin showed a trend 
toward benefit, with an overall risk reduction by 17% [6]. 
When compared with vasopressin, somatostatin was 
equivalent in terms of efficacy in controlling bleeding but 
had significantly fewer adverse effects [7]. A study by 
Villaneuva [8,9] compared somatostatin alone with 
combinated therapy of somatostatin and scerotherapy. 
This study observed the greatest benefit of combinated 
therapy somatostatin and scperotherapy. Unfortunately, 
somatostatin is not available in the United States. 
Octreotide, a somatostatin analog is available in 
United States. It has similar properties as somatostatin, 
but with a longer biological half-life. Results regarding its 
efficacy compared with placebo, sclerotherapy, and 
balloon tamponade have been inconsistent. Many of the 
studies were small, low quality, and unblinded. A recent 
meta-analysis [10] demonstrated that octreotide was 
superior to other alternative therapies (placebo, 
vasopressin/terlipressin or sclerotherapy) in controlling 
acute variceal bleeding. Because of its excellent safety 
profine, octreotide has an added benefit that it can be 
administered in outside of the intensive care unit 
setting.[11] Continuous intravenous infusion of octreotide 
(100ug bolus, followed by 50-100ug/h) reduces 
splanchnic blood flow and portal blood pressures and is 
effective in the initial control of bleeding. It is administered 
promptly to all patients with active upper gastrointestinal 
bleeding and evidence of liver disease or portal 
hypertension until the source of bleeding can be 
determined by endoscopy.  
Terlipressin is a long acting triglycyl-lysine 
derivative of vasopressin. It is transformed slowly to 
vasopressin by enzymatic cleavage. Because of this slow 
release to the active agent, terlipressin has significantly 
fewer adverse effects then vasopressin. Terlipressin is the 
pharmacologic therapy that has been shown to reduce 
mortality in acute variceal hemorrhage compared with 
placebo [12]. Unfortunately, terlipressin is not available in 
the United States. 
 
Endoscopic management 
Both sclerotherapy and band ligation are very 
effective in controlling acute esophageal variceal bleeding 
and preventing rebleeding during the hospitalization 
[13,14]. These two modalies are the mainstay of therapy, 
and they are successful in achieving hemostasis in 80% 
to 90% of the patients with acute variceal bleeding [15]. 
The advantages of sclerotherapy include its ease of use, 
especially during massive bleeding, and its lower cost. 
Sclerotherapy, however, has been associated with 
ulceration and bleeding, bacteremia and stricture 
formation [16,17]. Band ligation has a lower rate of 
complication, but it can be difficult to use during acute 
bleeding [19]. A more recent study by Avgerinos and 
colleagues demonstrated what after initial control of 
bleeding; band ligation had significantly fewer rebleeding 
rates and complications, and it a achieved eradication 
with fewer endoscopic sessions than sclerotherapy [20]. 
Therefore, wherever feasible, band ligation should be the 
first-line endoscopic therapy for acute variceal bleeding 
[21,22]  
 
Transjugular Intrahepatic Portosystemic Shunt (TIPS) 
TIPS is indicated in situations when acutely 
bleeding varices are refractory to medical therapy. TIPS 
has been shown in this situation to control bleeding in 
95% of cases with a rebleed rate of only 18%. 
Furthermore, a study by Vangeli and colleagues reviewed 
15 studies involving the use of TIPS to control bleeding 
when medical therapy failed. Similar to previous reports, 
bleeding was controlled in 93.6% of patients, and rebleed 
within 7 days was low (12.4 %) [23]. The mortality rate, 
however is between 30% and 40%. This is likely because 
patients with continued bleeding tend to be quite ill and 
have a high mortality rate despite any intervention. 
 
Surgery 
Surgical options include selective portosystemic 
shunting, calibrated H grafts and devascularization 
procedures. The 30 – day mortality rate, however, 
approaches 80% with these procedures. Therefore, in 
most situations, surgical intervention for acutevariceal 
bleeding should be reserved for when medical thepay fails 
and TIPS is not available. Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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Fig. 1 outlines a reasonable algorithm for the management of acute variceal hemorrhage. 
 
A Cirrhotic with Upper GI bleeding 
 
Volume Resuscitation 
 
Begin Intravenous Antibiotics and 
Somatostatin or Actreotide or Terlipressin 
 
Upper Endoscopy 
 
Endoscopic Band ligation (preferred) or Sclerotherapy 
 
Hemostasis Achieved? 
                                   YES               NO 
 
 
 
 
 
 
 
Conclusions 
 
Portal hypertension causes bleeding from 
varices (most commonly esophageal) or portal 
hypertensive gastropathy. Less than one-third of patients 
with portal hypertension and varices will develop acute 
bleeding. However, these lesions account for 10-20% of 
significant gastrointestinal hemorrhages, with a hospital 
mortality rate of 15-40%. If untreated, 50% will rebleed 
during hospitalization. When patients who have cirrhosis 
present with GI bleeding, they shoul be resuscitated and 
receive octreotide or other vasoactive agents. Endoscopy 
shoul be performed promptly to diagnose the source of 
bleeding and to provide endoscopic therapy (preferably 
banding). The currently available treatment for acute 
variceal bleeding provides hemostasis in most patients 
(90%).  
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